



**Australian  
Clinical  
Trials  
Alliance**

# ADAPTIVE PLATFORM TRIALS WORKSHOP

## Background

Adaptive Platform trials (APT's) allow for the efficient evaluation of modern treatments, with fewer patients, less time, and with greater probability of success than some traditional study designs.<sup>1</sup> However, they can be difficult to conduct efficiently due to additional administrative and logistical complexities, financial needs,<sup>2</sup> and statistical difficulties. There is a need to improve awareness and understanding of different APT designs and statistical protocols.

## ACTA's Role

The Australian Clinical Trials Alliance (ACTA) facilitated an in-person APT workshop on November 7, 2022. The workshop was highly successful and popular; it was oversubscribed with a waiting list, demonstrating the immense demand and popularity in this area of innovative trial designs.

## WHAT HAVE WE DONE?



### In-person half-day workshop

#### 1) Speaker presentations:

- + What questions are suitable for a platform trial?
- + Designing a platform trial (structure, role of simulation)
- + Operational aspects of platform trials
- + Organisational, management, governance, Data Safety Monitoring Committee, interim analyses
- + Consumer engagement and involvement

#### 2) Three panel discussion sessions

#### 3) Two clinic presentations on early-stage platform trials + live panel feedback

## OUR PANELISTS/SPEAKERS



Prof Steve Webb



Dr Colin McArthur



Dr Julie Marsh



Mr Mitch Messer



Mr Arlen Wilcox



Prof Katherine Lee



Prof Ian Marschner



## Maximum capacity - 70 attendees



\*Other includes government, consumer, not-for profit organisation and industry  
^ includes Research Institutes and Coordinating Centres

\*Other includes executive officer, support officer, research governance officer, student, consumer, physicians, policy officer and project officers.  
~ includes Professor/Associate Professor/Research Fellow/Researcher  
^ includes Coordinators  
# includes Head, CEO and Lead

1. [https://journals.sagepub.com/doi/10.1177/1740774515626362?url\\_ver=Z39.88-2003&rfr\\_id=ori%3Arid%3Aacrossref.org&rfr\\_dat=cr\\_pub++0pubmed](https://journals.sagepub.com/doi/10.1177/1740774515626362?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Aacrossref.org&rfr_dat=cr_pub++0pubmed)

2. <https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-019-1391-9>

# WHAT WAS THE IMPACT?



**90%** indicated overall that the workshop improved their awareness and understanding of innovative trial design to a moderate or great extent



**98%** found the workshop content useful and relevant and were either satisfied or extremely satisfied with the discussion and topics presented in the



**76%** felt that the workshop has impacted their readiness to utilize an innovative trial design (i.e. an adaptive platform trial) to a moderate or great extent

## NEXT STEPS...

### + Virtual APT clinics hosted by ACTA

Commencing in 2023, we are excited to host presentations on early stage adaptive platform trials with live expert panel feedback. Please send us your Expression of Interest via email, outlining your study (3-4 lines) to us.



### + Case studies

Interested to showcase your adaptive platform trial and how ACTA has helped you? Please get in touch with us.

Want more information? Please email ACTA at [acta@clinicaltrialsalliance.org.au](mailto:acta@clinicaltrialsalliance.org.au)

